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Abstract
Background: Pain is one of cancer patients’ most frequent and distressing symptoms; however, analgesics’ side
effects often increase symptom burden. Further, with the home rapidly becoming the primary cancer care setting,
family caregivers (FCs) commonly play central roles in patients’ pain self-management, but with little or no preparation.
One US-tested intervention, the PRO-SELF© Plus Pain Control Program (PCP), designed to support cancer outpatients
and their FCs in pain self-management, is currently being tested in the Swiss multi-centre PEINCA study. The current
PEINCA-FAM study is a sub-study of PEINCA. The aims of PEINCA-FAM are: a) to test the efficacy of the adapted
German PRO-SELF © Plus PCP to reduce side effects of analgesics; b) to enhance patients’/FCs’ knowledge regarding
cancer pain; and c) to explore FCs’ involvement in patients’ pain self-management.
Methods: This mixed methods project combines a multi-centre randomized controlled clinical trial with qualitative
data collection techniques and includes 210 patients recruited from three oncology outpatient clinics. FCs involved in
patients’ pain self-management are also invited to participate. After baseline evaluation, eligible participants are
randomized to a 6-week intervention group and a control group. Both groups complete a daily pain and symptom
diary. Intervention group patients/FCs receive the weekly psychoeducational PRO-SELF© Plus PCP interventions;
control group patients receive usual care. After completing the six-week study procedures, a subsample of 7–10
patients/FCs per group and hospital (N = 42–60) will be interviewed regarding their pain management experiences.
Data collection will take place from April 2016 until December 2018. An intent-to-treat analysis and generalized linear
mixed models will be applied. Qualitative data will be analysed by using interpretive description. Quantitative and
qualitative results will be combined within a mixed method matrix.
Discussion: In clinical practice, specially trained oncology nurses in outpatient clinics could apply the intervention to
reduce side effects and to enhance patients’/FCs’ self-efficacy and pain management knowledge.
Trial registration: The PEINCA study is registered in the Clinical Trials.gov site (code: NCT02713919, 08 March 2016).
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Background
Cancer pain and analgesics’ side effects management
Pain is one of cancer patients’ most frequent and distres-
sing symptoms. However, analgesics’ side effects often
increase symptom burden [1, 2]. The International Associ-
ation for the Study of Pain defines pain as “an unpleasant
sensory and emotional experience associated with actual
or potential tissue damage, or described in terms of such
damage” [3]. World Health Organization (WHO) guide-
lines note that the main focus of pain management is anal-
gesics. As depicted in Table 1, these guidelines focus on a
3-step progression of analgesics from non-opioids to
strong opioids, which are associated with burdensome side
effects [4, 5]. For opioids, the most common of these side
effects are constipation, nausea, emesis, and concentration
difficulties; the most feared, though very rare, are respira-
tory depression and death. However slight the risk, fear
may still lead to early discontinuation, underdosing, or
otherwise inadequate analgesia [6, 7].
Although pain is a treatable symptom, up to 40% of
cancer patients experience inadequate pain manage-
ment. System-level barriers include limited access to
pain specialists or opioids [8] and misconceptions of
healthcare professionals (e.g., misconceptions and
knowledge gaps concerning pain management [9]).
Patient-level barriers can be divided into four groups:
cognitive (e.g., lack of information), affective (e.g.,
stress, anxiety, depression), sensory (e.g., analgesics’
side effects) and practical (e.g., implementing pain
management in everyday life) [10]. Family caregivers
(FCs) directly involved in patients’ pain management
commonly experience the same barriers as the patient.
FCs are defined as relatives, partners, friends, or neigh-
bours who provide care to patients [11].
With the home becoming the primary setting for
many aspects of cancer care, a key goal is to improve pa-
tients’ pain and side effect self-management [12]. Self-
management consists largely of strategies for solving
problems, making decisions, taking action, utilizing re-
sources, forming patient/healthcare provider partner-
ships, and dealing with physical and psychological issues
to avoid or delay deterioration [13, 14]. FCs commonly
play central roles in patients’ pain self-management.
However, while FCs may administer medications, imple-
ment pain relief strategies, and provide emotional sup-
port [10, 15], they often assume their tasks with little or
no preparation, knowledge, resources, or skills [16]. The
psychological and physical costs include a high preva-
lence of anxiety and depression, social isolation, sleep
disturbances, fatigue, and even an elevated risk of coron-
ary heart disease [17–19]. The responsibility for pain
management without corresponding skills often results
in FCs’ loss of self-efficacy [20]. Self-efficacy is defined
as the confidence in one’s ability to perform the behav-
iours necessary to achieve a target outcome [21]. Recent
studies on cancer pain management reveal that high
self-efficacy improves both patients’ well-being and FCs’
mood [22, 23]. However, little research has focused on
FCs’ influence and self-efficacy vis à vis supporting
self-management of pain and analgesics’ side effects in
cancer outpatients.
Supporting self-management of pain and analgesics’ side
effects
Three recent meta-analyses focusing on the effects of
psychosocial interventions to support cancer pain man-
agement from 1983 to 2012 found that, while gaining at-
tention, the psychosocial approach to pain management
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remains understudied [24–26]. The two most com-
mon intervention types were skill training and educa-
tion [25]. Regarding the main outcome measures, i.e.,
effects on pain intensity, pain interference in daily ac-
tivities, knowledge, and attitudes towards cancer pain
and analgesics, these meta-analyses revealed various
significant, though moderate overall improvements.
Further, a systematic evaluation of interventions’ con-
tent, structure, and efficacy to improve patients’
self-management of cancer pain revealed no discern-
ible patterns with respect to components, duration, or
delivery type or mode [27]. We found no studies that
focused on the side effects of analgesics.
To date, little research has focused on interventions
supporting FCs in patients’ cancer pain self-manage-
ment. First, Keefe et al. [28] tested the feasibility of a
partner-guided cancer pain management training pro-
gram with 78 end-of-life patients and their FCs. Inter-
vention group FCs showed significantly higher levels of
self-efficacy regarding support for the control of pain
and other symptoms. Second, in a randomized con-
trolled trial (RCT) of caregiver assisted coping skill
training for cancer patients and their FCs, Porter et al.
[29] reported significant results compared with an edu-
cation program. Additionally, enhanced knowledge of
cancer pain management led to both decreased anxiety
symptoms in both groups and increased symptom man-
agement self-efficacy in FCs. However, as this study
lacked a standard care control condition, these results
should be interpreted with caution. Third, Hendrix et al.
[23] tested an individualized training intervention on
self-efficacy in 120 patient-caregiver dyads. FCs in the
intervention group demonstrated significant increases
in self-efficacy regarding pain control, prevention of
infections, maintenance of nutrition, and practical
home care issues.
However, no studies have evaluated the effectiveness
of interventions focusing on analgesic side effect man-
agement to improve self-management in cancer patients
and their FCs. Similarly, no study has yet investigated
correlations between FCs’ cancer pain management
knowledge and self-efficacy related to pain management
and patients’ pain intensity.
The PRO-SELF© plus pain control program, PEINCA and
PEINCA-FAM
One psychoeducational intervention included in the
above-noted meta-analyses, the PRO-SELF © Pain Con-
trol Program (PCP), an intervention to support
self-management of pain in adult oncology outpatients
and their FCs, showed statistically significant and clinic-
ally meaningful reductions compared to standard care in
both average and worst-pain intensity in a large RCT (N
= 174) [30]. In further research, the intervention was
expanded regarding its duration (from 6 to 10 weeks)
resulting in the PRO–SELF © Plus PCP [31, 32]. Koller,
Miaskowski, De Geest, Opitz, and Spichiger [33] trans-
lated and adapted this version for use in German-speak-
ing populations. A pilot RCT using 39 oncology
outpatients yielded a statistically significant increase in
test subjects’ knowledge and demonstrated this version’s
feasibility. Based on the pilot RCT’s findings, the inter-
vention was adapted and is currently being tested within
the multi-centre “Mixed methods study to test the effi-
cacy of the adapted German PRO–SELF © Plus PCP, an
intervention directed at outpatients with cancer and
their family caregivers to reduce pain and related symp-
toms” (PEINCA) in Switzerland. The overall aim of the
multi-centre mixed methods PEINCA study is to evalu-
ate the efficacy of the adapted German PRO-SELF© Plus
PCP, which was designed to improve outpatients’ and
their FCs’ management of pain and pain intensity. The
purpose of this sub-study of PEINCA is to test the effi-
cacy of the adapted German PRO-SELF © Plus PCP at
both reducing analgesic side effects and enhancing can-
cer patients’ and FCs’ knowledge of cancer pain as well
as to explore their learning processes. In addition, FCs’
involvement in patients’ pain self-management and asso-
ciation between their self-efficacy and knowledge of can-
cer pain with the cancer patients’ pain intensity will be
investigated (PEINCA-FAM).
Theoretical framework
The overall framework of the PRO-SELF © Plus PCP
was the Theory of Symptom Management (TSM) [34]. A
further development of the TSM, the Symptom Manage-
ment Model (SMM, see Fig. 1), which depicts interacting
concepts, serves as the theoretical framework for this
study [35]. Precipitating factors (antecedents) such as
demographic, sociocultural and psychological character-
istics, can influence perceived symptoms at baseline (in-
tercepts) and over a given trajectory (slope). By charting
the trajectories of symptoms in relation to interventions
(symptom management strategies) and patient/FC/nurse
interactions, we can illustrate these interactions’ contin-
ued influence over patients’ and their FCs’ outcomes
(consequences). In this study, consistent with the SMM,
cancer pain is viewed as a complex, multidimensional
experience frequently accompanied by analgesics’ side
effects. Precipitating factors, e.g., social environments
and lack of knowledge, influence symptom trajectories.
Within the framework’s symptom management strategy,
our intervention focuses on supporting cancer patients’
pain and analgesic side effect self-management and the
involvement of FCs. Patients as well as FCs are seen as
key players who interact with intervention nurses.
Alongside improved knowledge of cancer pain and
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self-efficacy in FCs, reduction of analgesics’ side effects
is a key intervention outcome.
In addition, Bandura’s Social Cognitive Theory (SCT),
an adult learning theory, provided the supplementary
conceptual framework for the intervention [36]. SCT ac-
knowledges that learning is a cognitive process that
takes place in a social context and can occur through
processes of observation, with each individual possessing
a self-regulating system that affects motivation and
learner differentiation. As part of this system, Bandura
introduced the concept of self-efficacy [37], along with
major influencing factors: mastery experiences, live
modelling, performance exposure and positive appraisal
[21]. Through our intervention to educate cancer pa-
tients and their FCs, we aim to develop their knowledge
regarding pain management, their self-efficacy regarding
pain management, and their symptom self-management
skills. This entails keeping a diary, setting goals and es-
tablishing a management plan to reach those goals.
Aims
PEINCA-FAM aims to test the adapted German
PRO-SELF © Plus PCP pain self-management interven-
tion to reduce cancer outpatients’ analgesics’ side effects,
to explore patients’ and FCs’ knowledge of cancer pain
and their learning processes, and to investigate FCs in-
volvement in patients’ pain self-management and associ-
ations between their self-efficacy, knowledge of cancer
pain and patients’ pain intensity. Specific aims of this
study are: (1) to test the efficacy of the adapted German
PRO-SELF © Plus PCP to reduce analgesics’ side effects
by focusing on constipation, nausea, emesis and concen-
tration difficulties; (2) to test the efficacy of the adapted
German PRO-SELF © Plus PCP to improve knowledge
of cancer pain management in patients and FCs and to
qualitatively explore patients’ and FCs’ learning process
during the intervention; and (3) to explore the associ-
ation between FCs’ self-efficacy and knowledge of cancer
pain with patients’ pain intensity and to qualitatively ex-
plore FCs’ influence on patients’ pain self-management.
Methods
Study design
Embedded in the ongoing PEINCA study, the
PEINCA-FAM sub-study applies a mixed method ap-
proach. In a concurrent embedded strategy, an RCT is
combined with qualitative parts [38, 39]. All data are
generated within PEINCA. The following describes the
PEINCA study’s essential methods as they apply to
PEINCA-FAM.
Sample and setting
Patients with cancer pain are recruited from oncology
outpatient clinics at three university hospitals in the
German speaking part of Switzerland. These individuals
are included if they (1) are aged ≥18 years; (2) have expe-
rienced any type of recurrent cancer pain, i.e., rated ≥3
on a 0–10 Numeric Rating Scale (NRS, 0 = no pain, 10 =
worst imaginable) over the past week; (3) have an esti-
mated life expectancy of > 6 months; (4) are able to
understand, read and write German; and (5) have access
to a telephone. Participants are excluded if they (1) have
Fig. 1 Diagram of the Symptom Management Model. Note. The Symptom Management Model (SMM) [35]. Abbreviation: QoL = quality of life.
Copyright © gratefully received by Copyright Clearance Center’s RightsLink® service/ John Wiley and Sons
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cognitive dysfunction or hearing impairment; (2) are
hospitalized > 2 weeks during the study; and (3) are suf-
fering solely from neuropathic pain. To be eligible, FCs
must be (1) aged ≥18 years; (2) able to understand, read
and write German; and (3) willing to participate in all
intervention sessions.
Sample size determination
The results of the above-mentioned pilot study (Koller
et al. [33]) included a maximum mean alleviation of 0.99
NRS (0–10) for average pain and a mean alleviation of
1.27 NRS (0–10) for the worst pain compared to the
control group in week nine. For these two endpoints,
based on average pain improvement data, an alpha error
of 0.05 (95%) and a beta error of 0.2 (80%) would require
a 136-patient sample to achieve sufficient statistical
power. Estimating an attrition rate of 35% over the
6-week study period, it will be necessary to recruit a
total sample of 210 patients. We expect to recruit 50%
of patients along with FCs. This number will be suffi-
cient. Based on Wells, Hepworth, Murphy, Wujcik, and
Johnson [40], who assessed initial effects of an interven-
tion to increase knowledge and positive beliefs about
cancer pain management in patients using the Family
Pain Questionnaire (FPQ), an improvement in know-
ledge and beliefs were found [F (1,62) = 18.2, p < 0.001].
At an alpha error level of 0.05, a sample size of 32 FCs
should be sufficient to achieve a statistical power of 80%.
With respect to the sample size for the qualitative
part, a sample of 42–60 patients and FCs should supply
sufficiently redundant data to discover patterns, com-
monalities and differences among the groups.
Recruitment
Specifically trained nurses from the outpatient clinics
work as research assistants (RAs) for the study. All RAs
are experienced registered nurses or graduate students
in nursing who have received study-specific training by
the study coordinator (HR). RAs screen potential partici-
pants and verify inclusion criteria via patient files and
discussions (regarding life expectancy, etc.) with their
treating physicians. If the initial inclusion criteria are
met, the RAs contact the patients directly during their
outpatient appointment to check whether they have ex-
perienced repeated pain that they would rate on an NRS
as ≥3 over the last week, are able to understand, read
and write German, and have access to a telephone. The
RAs then inform patients about the study and invite
them to participate. Each patient is also asked if an FC is
involved in their daily pain self-management. If yes, the
FC is also invited to participate in the study. Written in-
formation and consent forms (including those for FCs, if
necessary) are then given to the patient. After at least
24 h, an RA contacts each patient (or patient/FC dyad)
again to provide verbal information to the FC as needed,
ask about their decision regarding participation, and col-
lect the signed written consent form. In all settings,
these written informed consent forms are stored safely
in the Investigator Site File (ISF) by the RAs. Only after-
wards are participants randomized to the IG or CG. Pa-
tients and FCs have the right to withdraw from the
study at any time without consequences.
Concerning the recruitment of participants for qualita-
tive data collection, all patients (and FCs) are asked at
the beginning of the main study whether they are willing
to participate in an interview following completion of
the study’s 6 weeks of procedures. At the end of the final
home visit, the intervention nurse (IN) or an RA asks
selected patients (and FCs) whether they are still willing
to participate in the interview. They then provide verbal
and written information and obtain written consent
from those who agree. Purposive sampling is applied to
ensure approximately equal sample sizes per study site,
as well as variation regarding pain intensity, intervention
adherence, age, gender, education, living situation, and
tumour entity.
Random assignment
As shown in Fig. 2, patients and FCs who have provided
written consent are stratified by site and randomized 1:1
either to a six-week intervention group (IG) or to a
usual care group (CG). A permuted block procedure,
with blocks of 2, 4 and 6, is used to create a computer
generated randomization list. This procedure should en-
sure approximately equal distribution of patients per
group and per centre. The Clinical Trial Unit (CTU) of
one of the included university hospitals provides the list,
which is accessible from all settings.
Blinding
Blinding is not possible because the INs use collected
data directly for the intervention (pain diary, Patient
Pain Questionnaire (PPQ)). And while treating physi-
cians are not informed, they may still become aware of
group allocation if participants ask questions or take
their diary to an appointment.
Intervention group and usual care group
Intervention group
The intervention is performed by four specially trained
oncology nurses. These INs have completed a Master’s
degree in nursing and are experienced clinicians in this
field of study. A two-day training segment provided by
the primary investigator (ES) included a review of
current pain management guidelines and detailed teach-
ing and training for each intervention component of the
adapted German PRO-SELF © Plus PCP.
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The intervention is intended to implement struc-
tured and tailored components of the German
PRO-SELF© Plus PCP and is based on three key strat-
egies: nurse coaching, skill building, and provision of
information via academic detailing [30, 41]. Academic
detailing focuses on enhancing baseline knowledge by
providing key information and positive reinforcement,
while stimulating the learner as an active partner [42,
43]. Structured intervention components focus on pa-
tients’/FCs’ education to monitor pain and analgesics’
side effects (e.g., nausea, emesis, constipation, concen-
tration difficulties, fatigue), to document analgesics
taken, and to use a one-week pillbox. They are also
trained to apply a script to communicate with clini-
cians when pain control is inadequate.
To identify patients’ and FCs’ pain management know-
ledge deficits, the INs check their baseline knowledge of
cancer pain and side effect management based on the re-
sults of the PPQ. To reinforce their education and en-
hance knowledge of cancer pain and side effects,
patients and FCs receive the PRO-SELF © Pain Control
Booklet, as well as individualized information.
Concerning the tailored intervention components, the
IN reviews each pain diary with the associated patient/
FC, assesses the appropriateness of the analgesic pre-
scription and the side effect management, and teaches
Fig. 2 Flow chart of patient recruitment. Note. Flow chart of patient recruitment
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the patient/FC how to adjust the prescribed analgesics in
response to changing pain conditions and side effects.
Adherence to analgesic medication instructions and the
IN’s recommendations is assessed and discussed with
the patient/FC at each subsequent visit, after which
modifications to the pain and side effect management
plan are made as needed. The intervention is provided
during in-home visits (baseline, weeks 1 and 6), followed
by weekly in-home or telephone visits. The number, type
(in-home visit or phone call) and frequency of visits are
determined by defined criteria as follows: pain score > 3
on an NRS, patient is dissatisfied with pain management,
patient adherence with pain medication or recommenda-
tions < 50%. If one or more of these criteria apply, the
IN schedules an in-home visit; if none apply, she sched-
ules a phone call. In addition, a reinforcement phone call
is scheduled after major changes to the pain manage-
ment plan.
For quality assurance and analysis, all intervention ses-
sions and phone calls are audio recorded. The primary
investigator and the study coordinator review audio re-
cordings of visits and report their observations using an
audit checklist based on the intervention protocol. In
order to enhance the intervention’s implementation, they
and the INs promptly discuss any deviations. They con-
tinue to monitor audiotapes until a 95% protocol adher-
ence rate is achieved. Afterwards, audio-recordings are
reviewed at random.
Usual care group
The CG participants receive usual care regarding pain
management by participating centres. The treating phy-
sicians assess pain and prescribe analgesics. However, if
participants raise concerns to RAs about pain or side ef-
fects, they are encouraged to contact their physicians.
No specific counselling is provided.
Data collection
Both quantitative and qualitative data will be collected
from March 2016 until December 2018. Patients in both
groups complete a daily pain and symptom diary; pa-
tients and FCs fill in questionnaires. The same 6-week
data collection protocol is applied via in-home visits at
baseline and during weeks 1 and 6. In the IG, data are
collected by the IN. In order to minimize diffusion of
the intervention to CG participants, an RA collects data
in the control group. Between in-home visits at baseline
and weeks 1 and 6, patients/FCs receive brief telephone
calls every second week, during which the RA ensures
that the pain diary is being completed on a daily basis.
Quantitative data: variables and measurement
Table 2 provides an overview of the study variables and
data collection points for patients and FCs.
Questionnaires employed in this study are applied in
their German versions, for which validity and reliability
have been established. The primary patient outcomes are
selected analgesics’ side effects (constipation, nausea,
emesis, and concentration difficulties), self-efficacy, and
knowledge of cancer pain management. Primary FC out-
comes are self-efficacy and knowledge of cancer pain
management. The secondary outcomes are patients’
average and worst-pain intensity. Anxiety, depression,
functional status, and cancer-related symptoms are mea-
sured as covariates. Our analytical models will also con-
trol for age, education, time since diagnosis and current
disease status.
Medical record review form
Clinical data from patients’ medical records include the
date of the initial diagnosis, type of tumour, existence of
any metastases (no/yes regarding localization of metasta-
ses), comorbidities, and completed or current tumour
therapy.
Patient/FC information questionnaires
These questionnaires assess socio-demographic data in-
cluding age, sex, living alone (yes/no), employment sta-
tus and educational level.
Pain management diary
A pain management diary is used to assess analgesics’
side effects for each 7-day period. Patients are asked to
rate 12 side effect items on an 11-point NRS (0–10: 0 =
no symptom experience; 10 = strongest imaginable
symptom experience). Our analysis will focus on consti-
pation, nausea, emesis, and concentration difficulties.
On a second 11-point NRS (0 = no pain; 10 = strongest
imaginable pain) patients also rate their daily average
and worst pain intensity.
Brief pain inventory
Pain intensity, i.e., average and worst pain, is measured
on 0–10-point NRSs, which are part of the German ver-
sion of the BPI. Daily pain scores will be averaged for
each week of the study. The BPI is a pain measurement
tool with reliability and validity established as excellent
[44, 45].
Constipation assessment scale (CAS)
The CAS, an 8-item self-report tool, is completed weekly
to measure the presence and severity of constipation (0
= no problem, 1 = some problem, 2 = severe problem).
The total possible score ranges from 0 (no constipation)
to 16 (severe constipation). A score of ≥2 will trigger the
use of a constipation management plan. This scale’s val-
idity and reliability have been established [46, 47].
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PPQ and FPQ
The nine-item PPQ measures individuals’ knowledge
of cancer pain. In cases of patient/FC dyads, a similar
tool, the FPQ, is used for the FC [48]. Each item is
scored using a 0–10-point NRS, with an overall/aver-
age score obtained by summing the items and divid-
ing by 9. Extensive psychometric testing of the PPQ’s
and the FPQ’s English versions has established excel-
lent validity and reliability [49, 50]. As a part of their
pilot study, Koller et al. [33] translated the English
PPQ/FPQ into German.
Self-efficacy questionnaire in cancer patients and family
caregivers
The Self-Efficacy Questionnaire includes 15 items meas-
uring perceived ability to manage specific aspects of pain
on a scale ranging from 10 (very uncertain) to 100 (very
certain). The questionnaire is separated in three sub-
scales: one for pain management, one for physical func-
tion and one for other symptoms. A total score is
calculated by summing the scores for each of the sub-
scales. To assess caregivers’ confidence regarding their
ability to support cancer pain management, a caregiver
version of the self-efficacy scale was used. This version is
identical to that applied in cancer patients except that
caregivers are asked to rate how confident they are that
they can support the control of patients’ cancer pain
[22]. Construct validity and reliability have been estab-
lished for these questionnaires [51, 52].
Hospital anxiety and depression scale (HADS)
The HADS, a non-diagnostic self-report screening in-
strument, is used to assess anxiety and depression symp-
tomatology. Based on two 7-item subscales, each using a
4-point (0–3) Likert-type scale, a score of 11 or more (of
a possible 21) on either subscale indicates significant
psychological morbidity (< 8 = clinically insignificant; 8–
10 = borderline; 11–21 = indicate significant psycho-
logical morbidity) [53].
Eastern cooperative oncology group performance status
(ECOG-PS)
The ECOG-PS measures functional status, i.e., the
capacity to perform a variety of activities considered
normal for most people. Developed in 1960, the scale
has been widely used in clinical trials and oncology
practice [54]. It consists of a single 5-point scale
using verbal descriptors (0 = “fully active”, 4 = “com-
pletely disabled”).
Qualitative data
Data from intervention sessions
All intervention sessions are audio recorded by the IN
who provides the intervention. The PhD student (SV)
then listens to these audio-recordings and transcribes all
relevant passages, that is, all that concern side effect
management, learning processes, or FC involvement.
Additionally, field notes serve as qualitative data.
Table 2 Study variables and measurement timetable












Demographics, patient Patient Information Questionnaire X X
Demographics, FC FC Information Questionnaire X X
Clinical data Medical Record Review Form X X
Average pain and worst pain Pain management diarya: Brief Pain Inventory
(BPI)
X X X X X
Pain alleviation through pain medication X X X X X
Pain interference with function X X X X X
Duration of pain
Bowel movements and use of
laxatives
Side-effects of pain and cancer treatment
Pain management diarya: X X X X X
Knowledge of cancer pain Patient Pain Questionnaire X X X
Family Pain Questionnaire X X X
Constipation Constipation Assessment Scale X X X X X
Self-efficacy Self-Efficacy Questionnaire in patients with cancer X X X
Caregiver version of the Self-Efficacy Questionnaire X X X
Anxiety and depression Hospital Anxiety and Depression Scale X X X
Functional status Eastern Cooperative Oncology Group Performance
Status
X X X
Note. aPain management diary: daily assessment of average and worst pain, pain alleviation, and pain interference with function via BPI Brief pain inventory as
well as duration of pain, bowel movements/ use of laxatives, side effects of pain and of cancer treatment via pain management diary
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Individual post-RCT interviews
Selected patients and FCs are interviewed by specially
trained nurses who are not yet involved in the study pro-
cedures. These nurses are experienced in conducting in-
dividual interviews and have been trained by the primary
investigator and the study coordinator. Following an
interview guide, they ask open-ended questions to ex-
plore patients’ and FCs’ experiences with pain manage-
ment and related interactions with clinicians. To better
understand the degree to which the intervention meets
individual needs and to identify remaining difficulties re-
garding pain management, participants in the IG are also
asked to discuss their perceptions of the study interven-
tion’s burdens and benefits.
Focusing on PEINCA-FAM, we hope to identify
remaining difficulties concerning side effect manage-
ment, to explore patients’ and FCs’ learning processes
during the intervention, and to explore the FCs’ involve-
ment and self-efficacy. Interviews, which last approxi-
mately 60 min, are audio recorded and transcribed in
standard German. So that relevant new topics can be in-
tegrated in the interview guide, analyses are performed
in parallel with data collection.
Data analysis
Quantitative data will be compiled and analysed using
SPSS 24.0. Data will be retrieved from the SecuTrial®
database. Data will be systematically examined for out of
range values and data inconsistencies. As appropriate,
descriptive statistics will be calculated, including means
and standard deviations for interval variables and fre-
quencies, as well as percentages for categorical variables.
An intent-to-treat analysis will be applied, using a sig-
nificance level of .05 [55]. Although premature with-
drawal is expected to be a random process, participants
who completed the study will be compared with those
who did not based on demographics, treatment group
and other salient variables.
Data analysis for aim 1
Generalized linear mixed models will be applied to de-
termine differences between the IG and the CG anal-
gesic side effect developments throughout the
intervention. This approach allows calculation of the
main group and time effects, and of group-by-time inter-
action. The influence of missing data on the model re-
sults will be examined using sensitivity analysis [56].
Change scores for each patient as well as Cohen’s d will
be calculated for each variable of interest.
Data analysis for aim 2
Our quantitative analysis will use descriptive statistics to
summarize PPQ/FPQ items’ distribution characteristics.
Generalized linear mixed models will be applied to
determine differences between the IG’s and the CG’s
knowledge of cancer pain management throughout the
intervention. The influence of missing data on the model
results will be examined using sensitivity analysis [46].
Change scores for each patient/FC as well as Cohen’s d
will be calculated for each variable of interest.
For qualitative data analysis, transcript data will be
stored and analysed in ATLAS.ti 7. Field notes and au-
diotapes of telephone calls, home visits and interviews
will serve as qualitative data to explore both the IG’s
and the CG’s the learning processes concerning know-
ledge of cancer pain and pain self-management. Data
will be analysed via interpretive description–an ap-
proach using stepwise, systematic and iterative process-
ing of data to arrive at a meaningful description and
interpretation [57].
Information from quantitative and qualitative data col-
lection will be combined within a mixed method matrix.
Qualitative and quantitative results related to each Ger-
man PPQ/FPQ item will be integrated in a final synthe-
sis [39, 58].
Data analysis for aim 3
For the quantitative analysis, to determine associations
between FCs’ pre- and post-intervention score changes
regarding self-efficacy, knowledge of cancer pain and
patients’ average and worst-pain intensity between the
two groups, we will calculate Pearson correlation
coefficients.
Qualitative data will be generated in the same way as
for aim 2 via field notes, recordings of telephone calls,
home visits and interviews. Data will be analysed by ap-
plying interpretive description [57].
Information from quantitative and qualitative data col-
lection will be combined within a mixed method matrix
and integrated in a final synthesis [39, 58].
Handling of data
Data are handled confidentially and stored in a locked
cabinet for 10 years. Data are anonymized by applying
numerical IDs. The master file with patient names and
associated ID numbers is kept secure. Only the study
team has access to the written and electronic data. With
regard to the final trial data set, only the primary investi-
gator, the study coordinator, the PhD student and the
person who enters the data will have access. In order to
communicate trial results to participants, health care
professionals and the public, we plan to publish results
of primary and secondary outcomes. Furthermore, the
study team and nurse managers of participating univer-
sity hospitals will be informed about study results via
scientific presentations in various settings.
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Discussion
This study is the first to evaluate the effects of a psy-
choeducational intervention to reduce analgesics’ side ef-
fects and to explore the involvement of FCs in pain
management in a sample of Swiss cancer outpatients
and their FCs. As with other chronic illnesses, cancer
places new demands on patients and their FCs to man-
age their care; however, to do so effectively requires spe-
cialized skills. Therefore, to achieve adequate pain and
side effect self-management, cancer patients and their
FCs require educational interventions. Their self-man-
agement support should focus on enhancing patients’
and FCs’ pain management knowledge and self-efficacy,
while improving their use of pain and side effect relief
strategies [24, 59, 60].
This RCT involves the evaluation of a multicompo-
nent self-management support intervention that com-
bines monitoring of pain, side effects and medication
based on nurse coaching via weekly in-home or tele-
phone visits, skill building, and information provision.
Compared to usual care, self-management support is
expected to result in improved control of pain and
analgesics’ side effects, as well as enhanced self-effi-
cacy and knowledge [61].
Previous qualitative studies on home cancer pain man-
agement have showed that cancer patients have to man-
age diverse analgesics’ side effects, which is an ongoing
multidimensional process [12, 32]. The complexity of
this process means that, in addition to strategies and
techniques for effective pain management, it is import-
ant to buttress both patients’ and FCs’ self-management
and self-efficacy via an effective, holistic side effect man-
agement regimen [12, 62].
The proposed psychoeducational intervention, the
PRO-SELF © Plus PCP, differs from previous attempts in
its interactive, multicomponent approach: (1) Following
evidence-based guidelines, a comprehensive pain assess-
ment–including rating scales alongside patient reports of
pain qualities, side effects, treatments and satisfaction
with pain relief–is performed first at baseline, then at
each contact [63]. (2) Because the side effects of cancer
treatment can severely impact pain self-management, we
focus particularly on information and coaching to man-
age those effects [7, 46]. (3) Based on an academic de-
tailing approach, this intervention focuses on adult
learning principles, providing not only key information
but also positive reinforcement to enhance baseline
knowledge. Furthermore, it stimulates the learner as an
active partner [42, 43]. (4) This intervention will train
cancer patients and their FCs to improve their own
self-efficacy and self-management by keeping a diary,
setting goals and establishing a symptom management
plan to achieve those goals. Overall, the described
combination of quantitative and qualitative data will
illuminate the proposed intervention’s efficacy, enhan-
cing the interpretation of its results and improving its
eventual implementation [64].
Previous evidence indicates that, while the recruitment
of oncology patients is rarely easy, it can be especially
challenging for studies involving symptom management
[65, 66]. Obstacles to recruitment can include the char-
acteristics of the patients themselves, the recruiting clin-
ician, the trial centre, the trial organization and the trial
design [67]. To increase enrolment, it is important to
provide detailed information about the study procedures
and the advantages and disadvantages of the interven-
tion [68]. The study coordinator visits the participating
departments regularly. Study information and news of
the ongoing process are shared regularly between study
team members; and the steering committee continuously
supervises the study procedures.
Further, previous research experiences have taught us
that, in this already strained population, minimizing par-
ticipation burden will likely increase enrolment while
remaining efficacious [65, 69]. Therefore, we have
reduced the original 10-week study period [33] to 6
weeks, and stress maximum flexibility in scheduling
home visits.
This study’s results will contribute to the understand-
ing of interventions designed to improve side effect
self-management, knowledge and self-efficacy in cancer
outpatients and their FCs. If efficacious, the proposed
intervention could be implemented in clinical practice to
reduce pain and analgesics’ side effects, while enhancing
patients’ and their FCs’ pain management skills and
knowledge.
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